blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1786265

EP1786265 - NOVEL COMPOSITIONS AND METHODS OF TREATMENT [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  15.10.2010
Database last updated on 06.07.2024
Most recent event   Tooltip15.10.2010Application deemed to be withdrawnpublished on 17.11.2010  [2010/46]
Applicant(s)For all designated states
GlaxoSmithKline LLC
One Franklin Plaza
200 North 16th Street
Philadelphia, PA 19102 / US
[N/P]
Former [2010/13]For all designated states
GlaxoSmithKline LLC
One Franklin Plaza 200 North 16th Street
Philadelphia, PA 19102 / US
Former [2007/21]For all designated states
SMITHKLINE BEECHAM CORPORATION
One Franklin Plaza P.O. Box 7929
Philadelphia, PA 19101 / US
Inventor(s)01 / AUGER, Kurt, R.
1250 South Collegeville Road
Collegeville, PA 19426 / US
02 / JACKSON, Jeffrey, R.
1250 South Collegeville Road
Collegeville, PA 19426 / US
03 / SUTTON, David
1250 South Collegeville Road
Collegeville, PA 19426 / US
 [2007/21]
Representative(s)Marshall, Cameron John, et al
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[N/P]
Former [2009/51]Marshall, Cameron John, et al
Carpmaels & Ransford 43-45 Bloomsbury Square
London WC1A 2RA / GB
Former [2007/21]Marshall, Cameron John, et al
Carpmaels & Ransford 43 Bloomsbury Square
London WC1A 2RA / GB
Application number, filing date05795363.030.08.2005
[2007/21]
WO2005US30788
Priority number, dateUS20040605549P30.08.2004         Original published format: US 605549 P
US20050694531P28.06.2005         Original published format: US 694531 P
[2007/21]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2006026597
Date:09.03.2006
Language:EN
[2006/10]
Type: A2 Application without search report 
No.:EP1786265
Date:23.05.2007
Language:EN
The application published by WIPO in one of the EPO official languages on 09.03.2006 takes the place of the publication of the European patent application.
[2007/21]
Search report(s)International search report - published on:US07.12.2006
(Supplementary) European search report - dispatched on:EP22.07.2009
ClassificationIPC:A61K31/517, A61K31/337, A61K31/351, A61K31/4375, A61K31/513, A61K31/7068, A61K31/282, A61K33/24, A61K45/06, A61P35/00, A61P9/00, A61P9/10, A61P29/00, A61P37/00
[2009/34]
CPC:
A61K31/517 (EP,US); A61K31/282 (EP,US); A61K31/337 (EP,US);
A61K31/351 (EP,US); A61K31/4375 (EP,US); A61K31/4985 (EP,US);
A61K31/513 (EP,US); A61K31/7068 (EP,US); A61K33/243 (EP,US);
A61K45/06 (EP,US); A61P29/00 (EP); A61P35/00 (EP);
A61P37/00 (EP); A61P9/00 (EP); A61P9/10 (EP) (-)
C-Set:
A61K31/282, A61K2300/00 (US,EP);
A61K31/337, A61K2300/00 (US,EP);
A61K31/351, A61K2300/00 (US,EP);
A61K31/4375, A61K2300/00 (US,EP);
A61K31/513, A61K2300/00 (EP,US);
A61K31/7068, A61K2300/00 (EP,US);
A61K33/24, A61K2300/00 (EP,US)
(-)
Former IPC [2008/03]A61K31/517
Former IPC [2007/21]A01N43/54
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2007/21]
Extension statesAL19.03.2007
BA19.03.2007
HR19.03.2007
MK19.03.2007
YU19.03.2007
TitleGerman:NEUE ZUSAMMENSETZUNGEN UND BEHANDLUNGSVERFAHREN[2007/21]
English:NOVEL COMPOSITIONS AND METHODS OF TREATMENT[2007/21]
French:NOUVELLES COMPOSITIONS ET PROCEDES DE TRAITEMENT[2007/21]
Entry into regional phase19.03.2007National basic fee paid 
19.03.2007Search fee paid 
19.03.2007Designation fee(s) paid 
19.03.2007Examination fee paid 
Examination procedure19.03.2007Examination requested  [2007/21]
01.12.2009Despatch of a communication from the examining division (Time limit: M04)
13.04.2010Application deemed to be withdrawn, date of legal effect  [2010/46]
07.06.2010Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2010/46]
Fees paidRenewal fee
19.03.2007Renewal fee patent year 03
25.08.2008Renewal fee patent year 04
25.08.2009Renewal fee patent year 05
25.08.2010Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]WO0116114  (CHEMOCENTRYX INC [US]) [A] 1-17 * claims 1-9 * * pages 26-42; compounds 1.11, 2.1, 2.2, 2.4, 3.1, 4.1-4.8, 5.1, 6.1,7.1 * * page 3, lines 25-29 * * page 16, lines 23,24 * * page 18, lines 3-7 * * page 19, line 33 - page 20, line 1 *;
 [X]WO02083143  (TULARIK INC [US], et al) [X] 1,3,4,10 * pages 34-162; examples 1-11 * * page 30, lines 9-12,21-26 *;
 [A]WO03076418  (X CEPTOR THERAPEUTICS INC [US], et al) [A] 1-17* claims 16,84,85 *;
 [PX]WO2005051922  (CHIRON CORP [US], et al) [PX] 1-4,10,11,13-17 * claims 1,31-33,35,38,39 * * page 27, lines 16-23 * * pages 41-45; table 1; compounds 2,3,7,10-24 * * page 27, line 32 - page 28, line 3 *;
 [E]WO2005117889  (ICOS CORP [US], et al) [E] 1-3,10-13,16,17 * claims 1,16 * * page 10, paragraph 33 * * page 18, paragraph 58 * * pages 20,21, paragraphs 61,62 * * page 37, paragraph 115 *;
 [A]  - MAZUCCO R ET AL, "American Association for Cancer Research - 93rd Annual Meeting. Immunotherapy, chemoprevention and angiogenesis. 6-10 April 2002, San Francisco, CA, USA", IDRUGS, CURRENT DRUGS LTD, GB, (20020401), vol. 5, no. 5, ISSN 1369-7056, pages 408 - 411, XP002371684 [A] 1-17 * page 410, column L, paragraph 4 *
 [A]  - BURRIS H III ET AL, "A phase I study to determine the safety and pharmacokinetics of intravenous administration of SB715992 on a once weekly for three consecutive weeks schedule in patients with refractory solid tumors.", EJC SUPPLEMENTS, & 12TH ECCO (EUROPEAN CANCER CONFERENCE); COPENHAGEN, DENMARK; SEPTEMBER 21-25, 2003, (200309), vol. 1, no. 5, ISSN 1359-6349, pages S172 - S173, XP008108112 [A] 1-17 * abstract *
 [A]  - JOHNSON RANDALL K ET AL, "SB-715992, a potent and selective inhibitor of the mitotic kinesin KSP, demonstrates broad-spectrum activity in advanced murine tumors and human tumor xenografts", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, & 93RD ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; SAN FRANCISCO, CALIFORNIA, USA; APRIL 06-10, 2002, (200203), vol. 43, ISSN 0197-016X, page 269, XP001537163 [A] 1-17 * abstract *
International search[X]US6545004  (FINER JEFFREY T [US], et al);
 [Y]WO03039460  (MERCK & CO INC [US], et al);
 [AP]WO03070701  (CYTOKINETICS INC [US], et al);
 [AP]WO2004034972  (CYTOKINETICS INC [US], et al)
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.